NDAORALTABLET
Approved
Jul 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRISORALEN (trioxsalen) is an oral psoralen medication approved in 1964 for photochemotherapy-responsive dermatological conditions. It functions as a photosensitizing agent that enhances skin response to ultraviolet A (UVA) light exposure. The drug is indicated for vitiligo, psoriasis, and other pigmentation disorders requiring controlled UVA phototherapy.
LOE Approaching
As a legacy dermatology product approaching loss of exclusivity, the brand team likely operates in maintenance mode with reduced headcount and focus on cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRISORALEN offers limited career advancement due to its legacy status and approaching loss of exclusivity. Employment on this product provides operational and commercial management experience but does not align with growth-oriented career trajectories in pharmaceutical companies.
Brand ManagerSales Representative
Worked on TRISORALEN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.